Skip to main content
Erschienen in: Acta Neurochirurgica 1/2012

01.01.2012 | Review Article

Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis

verfasst von: Thomas Gaberel, Cristian Magheru, Evelyne Emery, Jean-Michel Derlon

Erschienen in: Acta Neurochirurgica | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

To reassess the use of antifibrinolytics (AF) in the management of aneurysmal subarachnoid hemorrhage (SAH) in the setting of present-day treatment strategies.

Method

The authors conducted a systematic review of the literature and a meta-analysis. They reviewed the PubMed database and conducted a manual review of article bibliographies.

Results

Using a pre-specified search strategy, 17 relevant studies involving a total of 2,872 patients with SAH at baseline, from which data of 1,380 patients having received AF, were included in a meta-analysis. Pooled odds ratios of the impact of AF on functional outcomes, rebleeding, and cerebral infarction were calculated. Short-term use of AF (72 h or less) associated with medical prevention of ischemic deficit seems to yield better results on functional outcome than long-term use of AF, especially if not associated with a medical prevention of ischemic deficit. The risk of cerebral infarction is not increased by the short-term use of AF and the risk of rebleeding is decreased independently of the length of AF use.

Conclusions

The use of AF should be reconsidered in the setting of modern-era treatment strategies, as the short-term use associated with medical prevention of ischemic deficit decreases the rate of rebleeding and does not increase the risk of cerebral infarction, thus potentially yielding better protection against poor functional outcome.
Literatur
1.
Zurück zum Zitat Ameen AA, Illingworth R (1981) Anti-fibrinolytic treatment in the preoperative management of subarachnoid hemorrhage caused by ruptured intracranial aneurysm. J Neurol Neurosurg Psy 44:220–226CrossRef Ameen AA, Illingworth R (1981) Anti-fibrinolytic treatment in the preoperative management of subarachnoid hemorrhage caused by ruptured intracranial aneurysm. J Neurol Neurosurg Psy 44:220–226CrossRef
2.
Zurück zum Zitat Chandra B (1978) Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol 3:502–504PubMedCrossRef Chandra B (1978) Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol 3:502–504PubMedCrossRef
3.
Zurück zum Zitat Chowdhary UM, Carey PC, Hussein MM (1979) Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid. Lancet 1:741–743PubMedCrossRef Chowdhary UM, Carey PC, Hussein MM (1979) Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid. Lancet 1:741–743PubMedCrossRef
4.
Zurück zum Zitat Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J (1998) Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 50:876–883PubMed Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J (1998) Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 50:876–883PubMed
5.
Zurück zum Zitat Fodstad H, Liliequist B, Schannong M, Thulin CA (1978) Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol 10:9–15PubMed Fodstad H, Liliequist B, Schannong M, Thulin CA (1978) Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol 10:9–15PubMed
6.
Zurück zum Zitat Fodstad H, Forssell A, Liliequist B, Schannong M (1981) Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery 8:158–165PubMedCrossRef Fodstad H, Forssell A, Liliequist B, Schannong M (1981) Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery 8:158–165PubMedCrossRef
7.
Zurück zum Zitat Fogelholm R, Hernesniemi J, Vapalahti M (1993) Impact of early surgery on outcome after aneurysmal subarachnoid hemorrhage. A population-based study. Stroke 24:1649–1654PubMedCrossRef Fogelholm R, Hernesniemi J, Vapalahti M (1993) Impact of early surgery on outcome after aneurysmal subarachnoid hemorrhage. A population-based study. Stroke 24:1649–1654PubMedCrossRef
8.
Zurück zum Zitat Gelmers HJ (1980) Prevention of recurrence of spontaneous subarachnoid hemorrhage by tranexamic acid. Acta Neurochir 52:45–50CrossRef Gelmers HJ (1980) Prevention of recurrence of spontaneous subarachnoid hemorrhage by tranexamic acid. Acta Neurochir 52:45–50CrossRef
9.
Zurück zum Zitat Gibbs JR, O’Gorman P (1967) Fibrinolysis in subarachnoid hemorrhage. Postgrad Med J 43(506):779–784PubMedCrossRef Gibbs JR, O’Gorman P (1967) Fibrinolysis in subarachnoid hemorrhage. Postgrad Med J 43(506):779–784PubMedCrossRef
10.
Zurück zum Zitat Girvin JP (1973) The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Trans Am Neurol Assoc 98:150–152PubMed Girvin JP (1973) The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Trans Am Neurol Assoc 98:150–152PubMed
11.
Zurück zum Zitat Hijdra A, Vermeulen M, van Gijn J, van Crevel H (1987) Rerupture of intracranial aneurysms: a clinicoanatomic study. J Neurosurg 67:29–33PubMedCrossRef Hijdra A, Vermeulen M, van Gijn J, van Crevel H (1987) Rerupture of intracranial aneurysms: a clinicoanatomic study. J Neurosurg 67:29–33PubMedCrossRef
12.
Zurück zum Zitat Hillman J, von Essen C, Leszniewski W et al (1988) Significance of “ultra-early” rebleeding in subarachnoid hemorrhage. J Neurosurg 68:901–907PubMedCrossRef Hillman J, von Essen C, Leszniewski W et al (1988) Significance of “ultra-early” rebleeding in subarachnoid hemorrhage. J Neurosurg 68:901–907PubMedCrossRef
13.
Zurück zum Zitat Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE (2002) Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 97:771–778PubMedCrossRef Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE (2002) Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 97:771–778PubMedCrossRef
14.
Zurück zum Zitat Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP (1982) Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 11:337–343PubMedCrossRef Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP (1982) Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 11:337–343PubMedCrossRef
15.
Zurück zum Zitat Kassell NF, Torner JC, Jane JA et al (1990) The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: Surgical results. J Neurosurg 73:37–47PubMedCrossRef Kassell NF, Torner JC, Jane JA et al (1990) The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: Surgical results. J Neurosurg 73:37–47PubMedCrossRef
16.
Zurück zum Zitat Kaste M, Ramsay M (1979) Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 10:519–522PubMedCrossRef Kaste M, Ramsay M (1979) Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 10:519–522PubMedCrossRef
17.
Zurück zum Zitat Leipzig TJ, Redelman K, Horner TG (1997) Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg 86:220–225PubMedCrossRef Leipzig TJ, Redelman K, Horner TG (1997) Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg 86:220–225PubMedCrossRef
18.
Zurück zum Zitat Locksley HB (1966) Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. J Neurosurg 25:321–368PubMedCrossRef Locksley HB (1966) Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations. J Neurosurg 25:321–368PubMedCrossRef
19.
Zurück zum Zitat Maurice-Williams RS (1978) Prolonged antifibrinolysis: an effective nonsurgical treatment for ruptured intracranial aneurysms? Br Med J 1:945–947PubMedCrossRef Maurice-Williams RS (1978) Prolonged antifibrinolysis: an effective nonsurgical treatment for ruptured intracranial aneurysms? Br Med J 1:945–947PubMedCrossRef
20.
Zurück zum Zitat Milhorat TH, Krautheim M (1986) Results of early and delayed operations for ruptured intracranial aneurysms in two series of 100 consecutive patients. Surg Neurol 26:123–128PubMedCrossRef Milhorat TH, Krautheim M (1986) Results of early and delayed operations for ruptured intracranial aneurysms in two series of 100 consecutive patients. Surg Neurol 26:123–128PubMedCrossRef
21.
Zurück zum Zitat Ohkuma H, Tsurutani H, Suzuki S (2001) Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke 32:1176–1180PubMedCrossRef Ohkuma H, Tsurutani H, Suzuki S (2001) Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke 32:1176–1180PubMedCrossRef
22.
Zurück zum Zitat Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U (1997) Enzyme controlling medicines: introduction. Semin Thromb Hemost 23:493–501PubMedCrossRef Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U (1997) Enzyme controlling medicines: introduction. Semin Thromb Hemost 23:493–501PubMedCrossRef
24.
Zurück zum Zitat Pradilla G, Chaichana KL, Hoang S, Huang J, Tamargo RJ (2010) Inflammation and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg Clin N Am 21:365–379PubMedCrossRef Pradilla G, Chaichana KL, Hoang S, Huang J, Tamargo RJ (2010) Inflammation and cerebral vasospasm after subarachnoid hemorrhage. Neurosurg Clin N Am 21:365–379PubMedCrossRef
25.
Zurück zum Zitat 25-Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008 25-Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008
26.
Zurück zum Zitat Roos YB, for the STAR-study group (2000) Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology 54:77–82 Roos YB, for the STAR-study group (2000) Antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage: a randomized placebo-controlled trial. Neurology 54:77–82
27.
Zurück zum Zitat 27-Roos YB, Rinkel GJE, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD001245. doi:10.1002/14651858.CD001245 27-Roos YB, Rinkel GJE, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD001245. doi:10.​1002/​14651858.​CD001245
28.
Zurück zum Zitat Sengupta RP, So SC, Villarejo Ortega FJ (1976) Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg 44:479–484PubMedCrossRef Sengupta RP, So SC, Villarejo Ortega FJ (1976) Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg 44:479–484PubMedCrossRef
29.
Zurück zum Zitat Shucart WA, Hussain SK, Cooper PR (1980) Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. J Neurosurg 53:28–31PubMedCrossRef Shucart WA, Hussain SK, Cooper PR (1980) Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. J Neurosurg 53:28–31PubMedCrossRef
30.
Zurück zum Zitat Starke RM, Kim GH, Fernandez A (2008) Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 39:2617–2621PubMedCrossRef Starke RM, Kim GH, Fernandez A (2008) Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 39:2617–2621PubMedCrossRef
31.
Zurück zum Zitat Tovi D, Nilsson IM, Thulin CA (1973) Fibrinolytic activity of the cerebrospinal fluid after subarachnoid hemorrhage. Acta Neurol Scand 49:1–9PubMedCrossRef Tovi D, Nilsson IM, Thulin CA (1973) Fibrinolytic activity of the cerebrospinal fluid after subarachnoid hemorrhage. Acta Neurol Scand 49:1–9PubMedCrossRef
32.
Zurück zum Zitat Tsementzis SA, Hitchcock ER, Meyer CH (1990) Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir 102:1–10CrossRef Tsementzis SA, Hitchcock ER, Meyer CH (1990) Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir 102:1–10CrossRef
33.
Zurück zum Zitat Van Rossum J, Wintzen AR, Endtz LJ, Schoen JHR, de Jonge H (1977) Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol 2:238–242PubMedCrossRef Van Rossum J, Wintzen AR, Endtz LJ, Schoen JHR, de Jonge H (1977) Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol 2:238–242PubMedCrossRef
34.
Zurück zum Zitat Vermeulen M, Lindsay KW, Murray GD et al (1984) Antifibrinolytic treatment in subarachnoid hemorrhage. N Eng J Med 311:432–437CrossRef Vermeulen M, Lindsay KW, Murray GD et al (1984) Antifibrinolytic treatment in subarachnoid hemorrhage. N Eng J Med 311:432–437CrossRef
35.
Zurück zum Zitat Whitfield PC, Moss H, O’Hare D et al (1996) An audit of aneurysmal subarachnoid haemorrhage: earlier resuscitation and surgery reduces inpatient stay and deaths from rebleeding. J Neurol Neurosurg Psy 60:301–306CrossRef Whitfield PC, Moss H, O’Hare D et al (1996) An audit of aneurysmal subarachnoid haemorrhage: earlier resuscitation and surgery reduces inpatient stay and deaths from rebleeding. J Neurol Neurosurg Psy 60:301–306CrossRef
36.
Zurück zum Zitat Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27(5):335–371PubMedCrossRef Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27(5):335–371PubMedCrossRef
37.
Zurück zum Zitat Zacharia BE, Hickman ZL, Grobelny BT, DeRosa P, Kotchetkov I, Ducruet AF, Sander Connolly S Jr (2010) Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 21:221–233, ReviewPubMedCrossRef Zacharia BE, Hickman ZL, Grobelny BT, DeRosa P, Kotchetkov I, Ducruet AF, Sander Connolly S Jr (2010) Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 21:221–233, ReviewPubMedCrossRef
Metadaten
Titel
Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis
verfasst von
Thomas Gaberel
Cristian Magheru
Evelyne Emery
Jean-Michel Derlon
Publikationsdatum
01.01.2012
Verlag
Springer Vienna
Erschienen in
Acta Neurochirurgica / Ausgabe 1/2012
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-011-1179-y

Weitere Artikel der Ausgabe 1/2012

Acta Neurochirurgica 1/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.